Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Also now that RXII has transferred to the OTCQX higher level OTC there is no plans at the moment to uplist to the Nasdaq or else they would have done so. if they were to uplist I would say they will more likely do it when phase 3 starts or ends. That would be the best time to uplist to the Nasdaq.
About your point of dilution, if you invest in a lot of biotech stocks like I do it happens in all of them. Either you are a long term investor or you are a day trader. LIke I said if you are a day trader by all means sell. I'm a long term investor so I am going to hold long on all my shares.
Plus why would you sell now with dilution anyways? We have multi dose results coming out July 12th. This time not only safety , but actual efficacy. Also at the Symposium where they are announcing the results there will be big analysts. JPmorgan, Roth, Jefferies, etc. it's going to be huge. Why would you sell now anyways?
You can do whatever you like it is your money, but I will still hold long term. I am predicting good things after the analyst symposium final phase 1b multi dose results plus starting of phase 2.
Also I think more money should come into the stock after good news because RXII moved up to the new OTCQX exchange, which will bring a lot of new investors. Best of luck on whatever you decide to do!
I'm going to try and load up more shares before July 12th presentation!
This is your beloved StarCity capital LLC.at work. No executives listed it's probably a shell company.
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=222502242
Lawsuit is meaningless!
It has to be a good thing. That secret could be a partnering arrangement for one of the drugs in the pipeline for all we know. But for RXII to file this it has to be good!
matter of fact here is the definition from online:
Confidential Treatment Order - CTO
Confidential Treatment Order - CTO
An order that provides confidential treatment for certain documents and information, that a company would otherwise have to file. A confidential treatment order (CTO) is issued by the Securities and Exchange Commission (SEC) and may only be in effect for a certain period of time, rather than indefinitely.
Companies would typically seek a CTO in order to keep information that would otherwise put it at a disadvantage, a secret. For example, a company may apply for such an order to keep information regarding a pricing arrangement made with a partner, secret, since competitors finding out this information may go after the partner with a more competitive price.
I just read about this and it is filed by the SEC so that the company can keep a secret quiet so competitors can't find out. Why RXII would have filed something like this? your guess is as good as mine but it must be good news.
In order for RXII to get on the OTCQX exchange it had to have a third party analyst or investor support it or (DAD). Roth Capital Partners became RXII's third party to nominate the company. That means soon you should be seeing a report from Roth Capital soon as well!
Reverse split was being put out there by many but I knew it wasn' going to happen. The only way I would say the company would do a reverse split to uplist to the Nasdaq would be if phase 2 results were out and they were going into phase 3.
No worries just keep your eye on the prize July 12th when they announce multi dose results for RXI-109 and the phase 2 trial design for RXI-109 at the investor and analyst symposium.
This company should be acquired and held long term and forget about daily swings or changes. One day this will be trading 20+ down the line!
This is good news and was bound to happen! RXII has one of the best self delivering RNAi technology. I know I have said this many times but it's true.
Other RNA and RNAi companies use delivery vehicles like lipids, encapsulation, proteins and other methods to get the RNAi drug to the target location. RXII has built properties onto the RNAi drug that requires no delivery vehicle whatsoever. IMO that's game changing! This company is a long term buy and hold!
I set my buy at .0035 purposely so that if it goes up today it will trigger and knock it higher! If it goes lower then it won't trigger I will wait to add more shares at a cheaper price! I think though it will bounce back today!
I predict a bounce as well, because the short volume was huge again around 74 million of the shares were short out of 159 million shares traded. That's about half the float went short today! I predict a huge bounce back tomorrow in BMSN
Phase 1 single dose already came out and was positive usual 30 to 50% reduction of scarring and no negative effect on the wound healing process. That's important not only to stop scar formation but not to block the process entirely. So positive news.
phase 1 multi dose is the next catalyst on deck and will be reported and the analyst and investor Symposium held by RXII. They will discuss phase 1 multi dose results and phase 2 trial design. Also other members will talk about other ocular conditions they are targeting: macular degeneration, diabetic enema, PVR, Retinoblastoma(eye cancer in children) etc.
I think MM realize they can't hold it down anymore probably covering and going long!
Everyone that bought in the .0002's are selling and taking profit because they panic when they see a decline like this. It's okay to see this after so many days it ran up. Either way we got FDA news approaching and what you don't want to be is left out when the news hits!
yes they look at efficacy and safety like all other biotechs of course, but don't you think they would be more lenient since it is Aplastic Anemia. for example:
Sarepta Therapeutics works well, and the FDA is thinking about doing Accelerated approval for it because it is an unmet need. I'm just trying to show that biotechs that go after rare diseases have an easier time getting approval, than say those companies that go after cancer which already is crowded with drugs.
Look at DVAX going for Hepatitis B they showed good efficacy but safety was good too, but got rejected because more safety tests needed to be done. But the FDA is not worried because there are thousands of other treatments out there for hepatitis B.
Another example is Vivus and ARNA which both have horrendous side effects but got approved by the FDA why???? Because it has been 13 years for an obesity drug. Otherwise Vivus and ARNA would have probably been rejected if there were other drugs out there that were safer and had more efficacy.
There is always that risk in biotech with trials and FDA, everyone investing in biotech stocks knows this. But if you have been investing in biotech for as long as I have the FDA is more lenient on companies that target rare diseases that are orphan drug status.
Many feel there is a good chance for approval for an unmet medical need Aplastic Anemia which has no current therapy! Think about that the people suffering from this disease have no approved treatments from the FDA! Don't you think the FDA will be somewhat lenient?
I agree every time the ask is bought at .0045 it's followed by sells at .0044. They are trying to keep it from running!
It doesn't matter really. Normally when an IND application is filed the FDA reviews it and it can take up to 30 days sometimes less. So what's the difference if news is out tomorrow or 30 days from now, either way the news is coming. That's why BMSN has been going up!
I told people this was undervalued. I said that biotech stocks that target orphan diseases tend to go up higher than other biotech stocks. Aplastic anemia is an unmet medical need where the patient fails to produce enough red blood cells in the bone marrow. Hemaxellerate could be huge!
Also don't forget about the IND coming soon on the MIN technology for the breast cancer vaccine!
upswing is probably the anticipation of FDA approval to start phase 1 trial for Hemaxellerate for Aplastic Anemia in 10 patients that failed previous therapy with standard of care!
I think you are right sucks that deposited funds get put on hold for 3 days otherwise I could buy more BMSN before it runs up!
Read this line on the Min technology
"US Patent # 8,389,708 was granted to Min with regard to his invention of a method directed to the silencing of immunosuppressive cancer causing genes using short interfering RNA (siRNA) leading to an increase in the immune response, a decrease in tumor-induced immunosuppression and a decrease in in vivo tumor progression"
if anybody here knows about RNA technology it is coming to light right now. SRPT uses RNA technology PMO kind, and other companies like (RXII) symbol are using RNA interference to down regulate genes. RXII will begin phase 2 soon in anti scarring a $4 billion dollar market.
So this min technology uses siRNA, which is small interfering RNA to downregulate the disease and increase immune response. Biotechs are always risky so of course there is risk it may or may not work. But look at the stock price downside is limited and upside is unlimited!
Patience folks remember not only are we waiting for FDA approval to begin phase 1 for stem cells of Hemaxellerate for Aplastic Anemia (orphan disease). We are also waiting for IND submission for Breast cancer Vaccine (MIN technology) thereafter. Patience will pay off here!
Best thing to do is accumulate shares and go long! No point in trading it for less than pennies. Once PR hits of FDA approval this will go up and never look back!
You guys see the new form 4's filed today for yesterday! Stock options to buy millions of shares by CEO and directors etc. Very nice good things are coming soon IMO you don't want to be left out!
you want to know the reason on why it didn't go up? This is why!
http://otcshortreport.com/index.php?index=BMSN
Look on Friday how many people went short: 66% make no mistake they will more than likely have to cover on Monday!
That's right they are also filing an IND on the breast cancer vaccine in Q4 as well.
I agree with a lot of what you said except for the trials part. yes it is 3 to 4 years away from approval. But if you know most biotechs in phase 1 deal with only safety and that's it. What's unique with RXII is phase 1a and 1b act like a phase 2 because we actually just saw the efficacy for the single dose. If the multi dose comes out even more positive that reassure the technology even more.
The reasoning for the phase 2 is to go after keloids and advanced scars. While granted it is still risky, I think it is impressive the results we got yesterday for phase 1. Remember they only gave patients one injection of sd-rxRNA over 3 months. In 3 months it was able to reduce scarring significantly.
It's possible, short sellers could drive it down if FDA questions aren't satisfactory, but considering what Koos did I don't think the FDA will deny it. If you read the press release it says this
"As part of the response to comments, Regen BioPharma provided new data demonstrating efficacy of the HemaXellerate product at accelerating stem cell recovery after chemotherapeutic injury."
So while there is small chance the FDA may want more questions, I feel confident in the fact that Biomatrix added more efficacy data to prove their point. Therefore I am concluding that the FDA should have no problem allowing the dosing to begin.
Basically good news, but once FDA approves for Clinical trials to start and is satisfied with responses from BioMatrix then short covering for sure! I will still accumulate some more shares while I can!
http://otcshortreport.com/index.php?index=BMSN
There is still 30% or more short, but I agree with you on a big short squeeze with any positive news from the company on the stem cell trial!
http://otcshortreport.com/index.php?index=BMSN
According to your logic Breast cancer vaccine was announced Jan, FeB , March. Which it was not! Point made! Whether you choose to believe it or not because of agenda is choice, but I laid out the truth. Pr on breast cancer was in May!
Sipp I have tried explaining that many times already but short sellers want to believe that Q3 is not JULY, Aug, September. Just ignore them they have an agenda!
But I pointed out that's not true. Breast cancer vaccine for MIN patent put out a Press release on May 2013. That was last month, and guess what quarter we are in??? You guessed it Q2 2013. Q3 is when they will get response for FDA questions: July, Aug, September. If you choose not to believe this, that's okay I'm just showing you facts.
The timeline is way off. They are not going by their fiscal quarters do you know how I know? They released the breast cancer vaccine MIN patent in Q2 as they promised one month ago in May! That means Q2 in May 2013 = Q2 , So Q3 is July,Aug,September.
Upcoming Milestones
Response to FDA questions: Q3 2013
Initiate HemaXellerate trial: Q4 2013
Complete HemaXellerate trial: Q4 2014-Q2 2015
In license Min technology: Q2 2013
File IND on Min technology: Q4 2013
Initiate clinical trial on Min technology: Q4 2013
Complete clinical trial on Min technology: Q4 2014-Q2 2015
I bolded it up top so you can see the correct timeline!
BMSN is heading higher! time for investors to cover their shorts and go long!
Penny stocks and pink sheet stocks don't trade after hours!
BMSN is heading higher for all investors be ready to cover and go long!